Longitudinal trajectory of plasma p-tau217 in cognitively unimpaired subjects.

ABSTRACT:

Background

The advent of Alzheimer's disease-modifying drugs requires accurate biological diagnosis to identify candidates for these therapies. So far, the most promising single plasma biomarker is phosphorylated tau at threonine 217 (p-tau217). To understand its biological features, it is essential to know its longitudinal trajectory and factors influencing it in cognitively unimpaired subjects with no brain pathology.

Methods

We analyzed longitudinal plasma p-tau217 values (mean follow-up time = 768.3 days) in a cohort of 209 healthy volunteers. We have studied factors associated with plasma p-tau217 changes by using different linear mixed-effects models.

Results

In amyloid-negative cognitively healthy subjects (n = 151) carriers of ApoE ε4 allele had significantly

SUBMITTER: Martinez-Dubarbie F 

PROVIDER: S-EPMC11661039 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature